Leerink Partners Strengthens its M&A Team
Leerink Partners, a notable investment bank known for its healthcare specialization, is excited to announce the addition of two highly experienced professionals, Grant Curry and Jason Truman, to its biopharma mergers and acquisitions (M&A) division. As Senior Managing Directors, they will work under the leadership of Tom Davidson, Co-President and Co-Head of Global Investment Banking.
Commitment to Excellence in Advisory Services
As the firm approaches its milestone of 30 years in the industry, Leerink Partners remains steadfast in its commitment to providing exceptional advisory services to clients. Jeff Leerink, the Chairman and CEO, asserts that these new hires reflect a dedication to excellence and an ambition to be an invaluable partner to their clientele.
Strategic Expansion at a Pivotal Time
The recruitment of Curry and Truman follows a significant management-led buyout that took place recently. As the firm celebrates this transformative year, it is positioned to double its revenue compared to pre-buyout levels, charting a course for significant growth in the coming year.
Leveraging Industry Leadership
Leerink's expansion in the M&A arena is aligned with its mission to furnish clients with differentiated capabilities across various strategic objectives. The enhanced focus on M&A will draw upon Leerink's established leadership within the biopharma capital markets and its extensive industry knowledge, which is highly valued by clients.
Introducing the New Team Members
Jason Truman brings over two decades of investment banking experience to Leerink Partners. He has advised a diverse array of biopharma entities, both domestic and international, on M&A, divestitures, and capital raising. Before joining the firm, he served as a Senior Managing Director at Guggenheim Securities, where he significantly contributed to the growth of their biopharma M&A practice, while also gaining experience at notable firms such as Credit Suisse and Morgan Stanley.
Curry's Impact in M&A
Grant Curry, with a rich background in biopharma M&A and activism defense, has joined from Gordon Dyal & Co. During his time there, he advised on several renowned biopharma and healthcare transactions, serving both U.S. and European clients. Prior to his role at Gordon Dyal, he was integral to the Global Healthcare Group at UBS, showcasing his extensive capabilities in navigating complex financial transactions.
Collective Expertise
Over the years, the duo of Jason and Grant has collectively navigated over $230 billion in M&A transactions, making them valuable assets to the Leerink team. Their combined expertise equips Leerink Partners with the ability to deliver sophisticated judgment to clients, facilitating exceptional outcomes in the competitive landscape of biopharma mergers and acquisitions.
About Leerink Partners
Leerink Partners is a prominent healthcare investment bank committed to advancing client interests through innovative advisory solutions, capital raising capabilities, and industry insights. Since its inception, the firm has facilitated transactions totaling approximately $65 billion and has aided clients in raising over $170 billion, establishing a strong reputation as a trusted partner in healthcare.
For any inquiries, please contact Diane Vieira at (617) 918-4097 or Michael Schutsky at (646) 818-9251.
Frequently Asked Questions
Who are the new hires at Leerink Partners?
The new hires are Grant Curry and Jason Truman, who will serve as Senior Managing Directors in the biopharma M&A team.
What is the focus of Leerink Partners?
Leerink Partners specializes in providing advisory services and capital raising in the healthcare sector, particularly in biopharma mergers and acquisitions.
How has Leerink Partners positioned itself in the market?
Leerink Partners aims to capitalize on its expertise and leadership in biopharma capital markets to offer differentiated services to clients.
What is the experience of the new team members?
Both Grant Curry and Jason Truman have extensive backgrounds in investment banking, specifically within biopharma M&A, with over 20 years of experience each.
What is the significance of these hires?
The addition of Curry and Truman reinforces Leerink Partners' commitment to excellence and aims to drive significant growth for the firm in the coming year.
